Literature DB >> 11408234

Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers.

A T Chow1, C Fowler, R R Williams, N Morgan, S Kaminski, J Natarajan.   

Abstract

The safety and pharmacokinetics of a once-daily high intravenous dose of levofloxacin (750 mg) in 18 healthy volunteers were studied in a double-blind, randomized, placebo-controlled, single-center parallel group study. Levofloxacin was well tolerated, and higher maximum concentration of drug in serum and area under the concentration-time curve values were achieved. For difficult-to-treat infections, high daily doses of levofloxacin may be beneficial, and intravenous administration may be preferred in certain clinical settings, such as when treating patients in intensive care units, warranting further evaluation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408234      PMCID: PMC90611          DOI: 10.1128/AAC.45.7.2122-2125.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection.

Authors:  I W Klimberg; C E Cox; C L Fowler; W King; S S Kim; S Callery-D'Amico
Journal:  Urology       Date:  1998-04       Impact factor: 2.649

3.  Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.

Authors:  S C Chien; F A Wong; C L Fowler; S V Callery-D'Amico; R R Williams; R Nayak; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

4.  Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human plasma and urine.

Authors:  F A Wong; S J Juzwin; S C Flor
Journal:  J Pharm Biomed Anal       Date:  1997-03       Impact factor: 3.935

5.  A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.

Authors:  T M File; J Segreti; L Dunbar; R Player; R Kohler; R R Williams; C Kojak; A Rubin
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

6.  Noncompartmental determination of the steady-state volume of distribution during multiple dosing.

Authors:  I L Smith; J J Schentag
Journal:  J Pharm Sci       Date:  1984-02       Impact factor: 3.534

Review 7.  The clinical pharmacokinetics of levofloxacin.

Authors:  D N Fish; A T Chow
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

8.  Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections.

Authors:  R L Nichols; J W Smith; L O Gentry; J Gezon; T Campbell; P Sokol; R R Williams
Journal:  South Med J       Date:  1997-12       Impact factor: 0.954

9.  Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.

Authors:  S C Chien; M C Rogge; L G Gisclon; C Curtin; F Wong; J Natarajan; R R Williams; C L Fowler; W K Cheung; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

  9 in total
  23 in total

1.  Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.

Authors:  Tyree H Kiser; Dorie W Hoody; Marilee D Obritsch; Colleen O Wegzyn; Paulus C Bauling; Douglas N Fish
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 2.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection.

Authors:  O Murillo; M E Pachón; G Euba; R Verdaguer; F Tubau; C Cabellos; J Cabo; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

4.  Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus.

Authors:  O Murillo; A Doménech; A Garcia; F Tubau; C Cabellos; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

5.  Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.

Authors:  Aaron M Cook; Craig Martin; Val R Adams; R Scott Morehead
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

6.  Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin.

Authors:  Robyn Defife; Marc H Scheetz; Joe M Feinglass; Michael J Postelnick; Kimberly K Scarsi
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 7.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

Review 8.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.

Authors:  David T Chung; Cheng-Yuan Tsai; Shu-Jen Chen; Li-Wen Chang; Chi-Hsin R King; Ching-Hung Hsu; Kit-Mui Chiu; Hao-Chen Tan; Yu-Ting Chang; Ming-Chu Hsu
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

10.  Bactericidal activity of the combination of levofloxacin with rifampin in experimental prosthetic knee infection in rabbits due to methicillin-susceptible Staphylococcus aureus.

Authors:  Claudette Muller-Serieys; Azzam Saleh Mghir; Laurent Massias; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.